HLA-A and cancer: Furthermore, using NRASQ61K/HLA-A*01:01 as a model of a moderate affinity peptide that is refractory to X-ray crystallography, we outline an integrative pipeline for detailed characterization of the solution structure, conformational plasticity and HLA binding repertoire of clinically relevant neoepitope/HLA targets with desired features for cancer immunotherapy.